Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
HCP Jobs
Contact Us
EMJ Gold
search
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
HCP Jobs
Contact Us
EMJ Gold
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
Edition
European
US
Dermatology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
Dermatitis Artefacta Treatment
9
Mins
June 2024
Dermatitis artefacta (DA), also known as artefactual skin disease, is a rare psychocutaneous disorder characterised by…
Read more
12
Mins
23rd March 2021
Transient Cutaneous Alterations of the Newborn
At birth, the skin of the newborn suddenly comes into contact with the extrauterine world: a dry and aerobic environment.1 Newborn skin is 40–60%…
14
Mins
15th March 2021
Syphilis Diagnosis and Treatment: State of The Art
Syphilis is a chronic bacterial infection caused by Treponema pallidum subspecies pallidum, known by clinicians for hundreds of years and with more than 5 million new cases diagnosed every year worldwide…
11
Mins
25th February 2021
Clinical Considerations Based On 5-Year Efficacy and Safety Data for the IL-23p19 Inhibitor Tildrakizumab
The indicative scaly, erythematous plaques of plaque psoriasis arise because of abnormal interactions between immune system cells and epidermal…
9
Mins
18th February 2021
Biological and Clinical Impacts of Ultraviolet-A on the Skin: New Insights
Terrestrial solar UVR consists of UVA (320–400 nm) and UVB (280–320 nm; typically around 295–320nm because of attenuation by the ozone…
11
Mins
10th February 2021
Long-term Efficacy and Safety of Tildrakizumab: 5-year Results from the reSURFACE 1 and 2 Phase III Trials in Patients with Moderate-to-severe Plaque Psoriasis
Psoriasis, a chronic systemic inflammatory disease with skin manifestations, can be an impediment to daily life. Accordingly…
8
Mins
15th December 2020
The Other Side of the Moon: A Clinical Dialogue on the IL-23 Pathway
Prof Reich began by highlighting how insights into the pathophysiology of psoriasis have led to the development and expansion of cytokine-targeted…
6
Mins
15th December 2020
Latest Highlights on Biologic Treatments for Psoriasis and Psoriatic Arthritis from EADV 2020
The VOYAGE 1 trial1 was a placebo- and active-controlled Phase III study to evaluate long-term efficacy and safety of the IL-23p19 inhibitor guselkumab…
8
Mins
15th December 2020
Bimekizumab Efficacy and Safety in Patients with Moderate-to-Severe Plaque Psoriasis
Psoriasis is a Th17-driven disease, with both IL-17A and IL-17F playing a pivotal role in its pathogenesis.2,3 BKZ is a monoclonal IgG1 antibody…
Loading posts...
« Previous
1
…
6
7
8
9
10
…
25
Next »